26-A-15266-ACC POOLED SAFETY ANALYSIS OF ZILEBESIRAN, AN INVESTIGATIONAL LONG-ACTING RNA INTERFERENCE THERAPEUTIC, FROM PHASE 2 STUDIES IN PATIENTS WITH HYPERTENSION